Afterload-Adjusted Strain Improves Risk Stratification Beyond Structural Remodeling in Mixed Aortic Valve Disease

Jonghee Sun, MD, Jiesuck Park, MD, MinJung Bak, MD, Hong-Mi Choi, MD, In-Chang Hwang, MD, Yeonyee E. Yoon, MD, PhD, Goo-Yeong Cho, MD, PhD

Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea

Address for correspondence:

Jiesuck Park, MD

Department of Cardiology, Cardiovascular Center

Seoul National University Bundang Hospital

82, Gumi-ro 173beon-gil, Seongnam, Gyeonggi-do, 13620 Republic of Korea

Tel: 82-31-787-7865

E-mail: cardio.jspark@gmail.com

Table / Figures: 4 / 5

Word count:

Funding: None declared

ABSTRACT

Background: Mixed aortic valve disease (MAVD) exposes the left ventricle (LV) to combined pressure and volume overload, which may not be adequately captured by conventional valve-centric parameters. We evaluated an integrated echocardiographic framework incorporating ventricular geometry and afterload-adjusted myocardial performance to better characterize LV adaptation in MAVD.

Methods: We retrospectively analyzed 950 patients with moderate or greater aortic stenosis categorized by aortic regurgitation (AR) severity. The integrated geometry index (IGI) was defined as the z-standardized sum of relative wall thickness and indexed LV end-diastolic volume. Afterload-adjusted strain (AAS) was calculated as absolute LV global longitudinal strain multiplied by estimated LV systolic pressure (systolic blood pressure + aortic valve mean pressure gradient), followed by z-standardization. The primary outcome was all-cause death or heart failure hospitalization; the secondary outcome was aortic valve replacement (AVR).

Results: During a median follow-up of 3.5 years, 122 primary events occurred. Increasing AR severity was associated with progressive LV remodeling and higher IGI, whereas AAS remained similar across MAVD phenotypes. IGI was associated with AVR but not with the primary outcome. In contrast, lower AAS was independently associated with the primary outcome (adjusted HR 1.59 per unit decrease, 95% CI 1.30–1.96; p<0.001) and improved discrimination beyond clinical variables (AUC 0.69 vs. 0.62). These associations were consistent across MAVD phenotypes and LV remodeling patterns.

Conclusions: In MAVD, afterload-adjusted myocardial performance provides independent and incremental prognostic value beyond structural remodeling. Incorporating AAS may improve risk stratification and complement conventional valve-centric assessment.

Keywords: Mixed aortic valve disease; Pressure-volume loading; Afterload-adjusted strain;

Echocardiography

1. INTRODUCTION

Mixed aortic valve disease (MAVD), characterized by the coexistence of aortic stenosis (AS) and aortic regurgitation (AR), represents a complex valvular condition in which the left ventricle (LV) is simultaneously exposed to pressure and volume overload. Chronic pressure overload related to AS promotes concentric remodeling, whereas volume overload from AR leads to LV dilation. The coexistence of these loading conditions may produce diverse structural adaptations of the LV and contribute to heterogeneous clinical trajectories.[1-3] Despite this complex pathophysiology, the echocardiographic evaluation of MAVD largely relies on parameters developed for isolated valve lesions. Conventional indices primarily provide a valve-centric assessment, focusing on the severity of AS or AR.[4] However, these parameters may not adequately reflect the integrated hemodynamic burden imposed on the LV in MAVD.[5] More importantly, such valve-focused parameters do not capture the impact of combined loading conditions on LV remodeling and myocardial performance. Recent studies have shown that myocardial remodeling and dysfunction are important determinants of clinical outcomes even in patients with moderate AS or AR.[6,7] These findings highlight the importance of evaluating the ventricular response to valvular loading beyond valve severity alone.[8] This approach may be particularly relevant in MAVD, where simultaneous pressure and volume overload necessitates integrated assessment of both ventricular geometry and myocardial performance.[2]

Accordingly, we developed an integrated echocardiographic framework to characterize MAVD. LV geometry reflecting combined pressure–volume loading was quantified using an integrated geometry index (IGI) derived from relative wall thickness (RWT) and indexed LV end-diastolic volume (LVEDVi). Myocardial performance was assessed using

afterload-adjusted strain (AAS), which incorporates LV global longitudinal strain (LVGLS) and afterload conditions, including systemic blood pressure and transvalvular pressure gradient. Using these complementary indices, we aimed to characterize LV adaptation in MAVD and evaluate their associations with clinical outcomes.

2. METHODS

2.1. Study Population

We retrospectively screened 4,477 consecutive patients who underwent transthoracic echocardiography at Seoul National University Bundang Hospital between January 1, 2015, and December 31, 2020, and were identified as having AS or AR. Patients with mild AS were excluded to focus on clinically relevant valvular loading conditions. Additional exclusion criteria included concomitant moderate or greater mitral stenosis or regurgitation, prior mitral or aortic valve surgery, bicuspid aortic valve, known cardiomyopathy, LV ejection fraction (LVEF) <40%, atrial fibrillation or flutter, cardiac implantable electronic devices, left bundle branch block, uncontrolled hypertension (systolic blood pressure >180 mmHg), severe pulmonary hypertension, poor echocardiographic image quality, or incomplete clinical or echocardiographic data. After applying these criteria, 950 patients with moderate or greater AS were included in the final cohort. Patients were further categorized according to the presence and severity of concomitant AR into three groups: (1) moderate or greater AS without AR, (2) moderate or greater AS with mild AR, and (3) moderate or greater AS with moderate or greater AR. The study flow and patient selection process are summarized in **Figure 1**. The study protocol complied with the Declaration of Helsinki and was approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB No. B-2511-1008-105). The requirement for informed consent was waived due to the retrospective nature of the study.

2.2. Echocardiographic Assessment

All echocardiographic examinations were performed by trained echocardiographers and

interpreted by board-certified cardiologists according to contemporary guideline recommendations as part of routine clinical care.[9] The severity of AS and AR was determined based on the final echocardiographic reports. AS severity was assessed using peak aortic jet velocity (AV Vmax), mean transaortic pressure gradient (AV mPG), and aortic valve area (AVA) calculated by the continuity equation.[4] AR severity was determined using an integrative approach based on available parameters, including color Doppler flow convergence, jet density, deceleration rate, diastolic flow reversal in the descending aorta, and vena contracta width.[10] Cardiac chamber quantification included LV end-diastolic diameter, interventricular septal thickness, posterior wall thickness, RWT, LV mass index (LVMI), LVEDVi, and LVEF. LV volumes and LVEF were calculated using the biplane Simpson method. Diastolic function was assessed using transmitral Doppler inflow and tissue Doppler imaging, including the E/e′ ratio. LVGLS was measured using two-dimensional speckle-tracking echocardiography with dedicated software (TomTec Image Arena 4.6, TomTec Imaging Systems, Munich, Germany; or EchoPAC PC BT20, GE Medical Systems, Horten, Norway). For the calculation of AAS, LVGLS was entered as an absolute value.[11,12]

2.3. Integrated Hemodynamic Assessment

To characterize the hemodynamic profile of MAVD, we constructed an integrated echocardiographic framework incorporating two complementary components: ventricular geometry reflecting combined pressure and volume loading, and myocardial performance adjusted for afterload conditions (**Figure 2**).

2.3.1. Integrated Geometry Index (IGI)

LV geometric remodeling under combined pressure and volume loading was quantified using IGI. RWT was used to represent concentric remodeling associated with pressure overload, whereas LVEDVi represented LV dilation associated with volume overload.[2] To integrate these complementary structural features, both parameters were standardized using z-transformation, and the IGI was calculated as the sum of the standardized RWT and LVEDVi values, with equal weight assigned to each component. Equal weighting was applied on the basis that RWT and LVEDVi represent mechanistically distinct but hemodynamically equivalent axes of LV geometric adaptation and that z-standardization ensures each component contributes proportionally to its variance within the study cohort, regardless of differences in absolute scale. A higher IGI reflects more advanced geometric remodeling, incorporating both concentric and dilated components.

2.3.2. Afterload-Adjusted Strain (AAS)

LV myocardial deformation was assessed using LVGLS obtained from two-dimensional speckle-tracking echocardiography. Given the load-dependency of LVGLS[12], particularly with respect to afterload, AAS was constructed to account for both systemic and valvular loading conditions. Effective LV systolic pressure was approximated as the sum of systolic blood pressure (SBP) and AV mPG. AAS was calculated as:

$$AAS\ (raw) = |GLS| \times (SBP + AV\ mPG)$$

where GLS is expressed as an absolute value (%), and SBP and AV mPG are in mmHg. Raw AAS values were subsequently standardized using z-transformation (mean 0, SD 1) for

statistical analyses. Higher AAS values indicate better myocardial deformation relative to afterload, whereas lower values indicate impaired afterload-adjusted myocardial performance.

2.4. Clinical Outcomes

The primary outcome was a composite of all-cause death or hospitalization for heart failure. The secondary outcome was aortic valve replacement (AVR), including both surgical and transcatheter interventions. Clinical events were ascertained through systematic review of hospital records using the institutional electronic medical database. Follow-up duration was defined from the index echocardiographic examination to the first occurrence of an outcome event or the last available clinical contact, whichever occurred first.

2.5. Statistical Analysis

Clinical and echocardiographic characteristics were compared according to MAVD phenotypes. Continuous variables are presented as median (interquartile range), and categorical variables as counts (percentages). Group comparisons were performed using the Kruskal–Wallis test for continuous variables and the χ^2 test for categorical variables. The distributions of IGI, AAS, and their component variables across MAVD phenotypes were illustrated using box-and-whisker plots. IGI and AAS were analyzed as both continuous variables and categorical variables based on their standardized values, with low defined as <0 and high as ≥0. Event-free survival for the primary outcome was estimated using the Kaplan–Meier method and compared using the log-rank test. Associations between echocardiographic indices and clinical outcomes were evaluated using Cox proportional hazards regression models. Hazard ratios (HRs) were

estimated for IGI and AAS as continuous and categorical variables. Multivariable models were adjusted for age, sex, and LVEF. To assess incremental prognostic value beyond a baseline clinical model (age, sex, and LVEF), receiver operating characteristic (ROC) curve analysis was performed. Discriminative performance was evaluated using the area under the curve (AUC) for predicting the 1-year risk of the primary outcome. Differences in AUC were compared using the DeLong test. All statistical analyses were performed using R software (version 4.5.1; R Foundation for Statistical Computing, Vienna, Austria). A two-sided p value <0.05 was considered statistically significant.

3. RESULTS

3.1. Baseline Characteristics According to MAVD Phenotypes

Baseline clinical and echocardiographic characteristics by MAVD phenotype are summarized in **Table 1**. Clinical characteristics were largely comparable across groups, although patients with moderate or greater AR tended to be younger and had a lower prevalence of diabetes. Both AV Vmax and AV mPG increased with increasing AR severity (both p<0.001), whereas AVA did not differ significantly among groups. With increasing AR severity, LV geometry progressively shifted from a concentric remodeling pattern toward a more dilated phenotype, characterized by larger LVEDD and LVEDVi and decreased RWT, despite no significant change in LVEF. Reflecting the combined changes in LVEDVi and RWT, IGI increased stepwise with increasing AR severity (p<0.001). In contrast, SBP and LV GLS did not differ significantly across MAVD phenotypes. Accordingly, AAS remained comparable between groups (p=0.649; **Figure 3**).

3.2 Clinical Outcomes According to MAVD Phenotypes, IGI, and AAS

During a median follow-up of 3.5 years (IQR 0.6–5.6), a total of 122 primary outcome events occurred, including 75 all-cause deaths. Event-free survival for the primary outcome did not differ significantly across MAVD phenotypes (log-rank p=0.900) (**Figure 4A**). Similarly, IGI was not associated with differences in event-free survival (log-rank p=0.800). In contrast, patients with low AAS showed a significantly higher incidence of the primary outcome (log-rank p<0.001). In Cox proportional hazards analyses, MAVD phenotypes were not associated with the primary outcome, consistent with conventional valve-centric parameters such as AV

Vmax and AV mPG (**Table 2**). IGI also did not show a significant association with the primary outcome (HR 0.97, 95% CI 0.83–1.13 per unit decrease, p=0.676). In contrast, AAS was strongly associated with the primary outcome (HR 1.58, 95% CI 1.32–1.88 per unit decrease, p<0.001), and this association remained significant after adjustment for age, sex, and LVEF (adjusted HR 1.59, 95% CI 1.30–1.96 per unit decrease, p<0.001). When analyzed categorically, low AAS was associated with a higher risk of the primary outcome compared with high AAS (adjusted HR 1.76, 95% CI 1.19–2.59, p=0.004).

For the secondary outcome, a total of 120 events occurred. Event-free survival differed significantly across MAVD phenotypes (log-rank p=0.020), with higher event rates observed in patients with increasing AR severity (**Figure 4B**). Patients with high IGI also demonstrated higher event rates compared with those with low IGI (log-rank p=0.040). In contrast, event rates did not differ according to AAS status (log-rank p=0.900). In Cox proportional hazards analyses, increasing AR severity, along with higher AV Vmax and AV mPG, was associated with a higher risk of the secondary outcome (all p<0.001; **Table 3**). IGI was also independently associated with the secondary outcome (adjusted HR 1.18, 95% CI 1.02–1.36 per unit increase, p=0.026). In contrast, no significant association was observed between AAS and the risk of the secondary outcome (adjusted HR 0.96, 95% CI 0.78–1.17, p=0.666).

3.3 Clinical Characteristics and Subgroup Analyses According to Afterload-Adjusted Strain

Given the significant association between AAS and the primary outcome, baseline clinical and echocardiographic characteristics were compared according to AAS status (**Supplementary Table 1**). Patients with low AAS were older and more frequently male compared with those

with high AAS (age 81 vs. 79 years, p=0.001; male 49.5% vs. 41.8%, p=0.021). Low AAS was also associated with a higher prevalence of prior myocardial infarction (6.9% vs. 2.1%, p=0.001) and heart failure (13.5% vs. 6.0%, p=0.001), whereas other clinical risk factors were comparable between groups. Blood pressure was lower in patients with low AAS. In terms of echocardiographic findings, patients with low AAS demonstrated lower LVEF (62 vs. 65%, p=0.001) and LVGLS (14 vs. 18%, p<0.001), and higher E/e′ (17 vs. 15, p=0.001). LV geometric parameters, including LVEDVi, LVMI, and RWT, were largely comparable between groups. The distributions of AS and AR severity were also similar, although the low AAS group showed slightly lower AV Vmax (3.4 vs. 3.7 m/s, p=0.001) and AV mPG (25 vs. 29 mmHg, p=0.001). Subgroup analyses demonstrated that the association between AAS and the primary outcome remained consistent across MAVD phenotypes and IGI strata after adjustment for age, sex, and LVEF (**Table 4**). Similarly, the association between lower AAS and the primary outcome was consistent across patients with and without prior myocardial infarction, heart failure, or subsequent AVR, with no significant interaction observed.

3.4 Incremental Prognostic Value of Afterload-Adjusted Strain

The discriminative performance for predicting the 1-year risk of the primary outcome was assessed using ROC curves (**Figure 5A**). The baseline clinical model, including age, sex, and LVEF, demonstrated modest performance (AUC 0.62; Model 1). The addition of IGI did not improve model discrimination (AUC 0.63; Model 2). In contrast, the addition of AAS significantly improved model performance (AUC 0.69; Model 3). This improvement remained significant when AAS was added to the model including both clinical variables and IGI (AUC 0.70; Model 4).

Spline curve analysis further demonstrated a graded association between AAS and the predicted risk of the primary outcome (**Figure 5B**). At a reference age of 70 years and LVEF of 50%, lower AAS values were associated with a progressively higher predicted risk, with a similar pattern observed in both sexes.

4. DISCUSSION

In this study, we evaluated an integrated echocardiographic framework for MAVD incorporating IGI, reflecting LV structural remodeling under combined pressure–volume loading, and AAS, reflecting afterload-adjusted myocardial performance. Three principal findings emerged. First, increasing AR severity was associated with progressive LV geometric remodeling, characterized by LV dilation, reduced RWT, and a stepwise increase in IGI. Second, despite increasing valvular loading, AAS remained comparable across MAVD phenotypes. Third, AAS was independently associated with the primary outcome and provided incremental discriminative value beyond conventional clinical parameters, whereas IGI was associated with the secondary outcome but not with the primary outcome.

4.1. Ventricular Remodeling and the Role of IGI in MAVD

In isolated AS, chronic pressure overload promotes concentric hypertrophy, whereas isolated AR induces eccentric remodeling with LV dilation. In MAVD, these competing loading conditions interact, with the predominant hemodynamic burden determining the resultant geometric phenotype.[2] In this study, increasing AR severity in the setting of moderate or greater AS was associated with a progressive shift toward a dilated LV phenotype, characterized by increased LVEDVi, reduced RWT, and a corresponding increase in IGI. These findings indicate that IGI effectively captures LV geometric adaptation under combined pressure–volume loading. The association between higher IGI and the secondary outcome likely reflects real-world clinical decision-making, whereby progressive LV remodeling and increasing hemodynamic burden prompt consideration of aortic valve intervention. In contrast, IGI was not associated with the primary outcome, suggesting that structural remodeling under

combined loading conditions, in the absence of myocardial dysfunction, may remain hemodynamically compensated.[13]

4.2. Afterload-Adjusted Strain and Myocardial Performance in MAVD

Although LVGLS is a sensitive marker of subclinical myocardial dysfunction in valvular heart disease, its load dependency limits interpretation in conditions of increased afterload.[12] This limitation is particularly relevant in MAVD, where afterload is determined by both systemic arterial pressure and the transvalvular gradient.[14] AAS addresses this limitation by scaling LVGLS to the estimated effective LV systolic pressure, approximated as the sum of SBP and AV mPG, thereby accounting for both systemic and valvular components of afterload.[15] Accordingly, AAS reflects myocardial deformation relative to the prevailing pressure load. In this study, despite increasing AR severity and higher transvalvular gradients, both LVGLS and AAS remained largely consistent across MAVD phenotypes, suggesting similar afterload-adjusted myocardial performance at the group level. However, lower AAS was consistently associated with the primary outcome across MAVD phenotypes, IGI strata, and regardless of subsequent AVR. In addition, AAS provided incremental prognostic value beyond conventional clinical parameters and IGI. These findings indicate that assessment of myocardial deformation in the context of afterload provides prognostic information beyond that obtained from valve-centric measures or structural remodeling alone.

Several prior approaches have attempted to incorporate loading conditions into the assessment of myocardial performance in valvular heart disease. Valvuloarterial impedance has been proposed to reflect global LV afterload but does not directly capture myocardial deformation.[16] Myocardial work indices, derived from pressure–strain loop analysis, provide a

more integrated assessment but require additional assumptions and specialized software, limiting their routine clinical applicability.[17] In this context, AAS provides a pragmatic alternative by integrating myocardial deformation with an estimate of effective LV systolic pressure using routinely available echocardiographic parameters. This simplicity may facilitate broader clinical implementation while preserving physiologic relevance.[14,15]

4.3. Limitations of Valve-Centric Assessment in MAVD

Conventional valve-centric parameters, including AV Vmax and AV mPG, are well-established predictors of disease severity and clinical outcomes in patients with isolated AS.[4] These indices provide robust assessment of the pressure overload imposed by a stenotic aortic valve and form the basis of current guideline recommendations. However, in MAVD, these may incompletely characterize the overall hemodynamic burden on the LV when pressure and volume overload coexist.[5] This limitation may attenuate their prognostic performance, particularly for outcomes related to myocardial dysfunction rather than valve severity alone.[8] In the present study, AV Vmax and AV mPG were not associated with the primary outcome, while remaining associated with the secondary outcome (AVR). This finding should be interpreted in the context of MAVD pathophysiology, in which LV remodeling and myocardial performance are influenced by the combined effects of pressure and volume loading. Taken together, these observations suggest that valve-centric parameters alone may be insufficient for risk stratification in MAVD and highlight the need for complementary indices that integrate ventricular remodeling and myocardial function.

4.4. Complementary Roles of IGI and AAS in MAVD Risk Stratification

The distinct associations of IGI and AAS observed in this study highlight the complementary roles of structural remodeling and myocardial performance in MAVD. IGI, reflecting LV geometric adaptation to combined pressure–volume loading, was associated with the secondary outcome, suggesting its relevance to clinical decision-making regarding valve intervention. In contrast, AAS, reflecting myocardial deformation adjusted for afterload, was independently associated with the primary outcome and provided incremental prognostic value. These findings underscore the distinction between structural adaptation and myocardial performance in MAVD. Current clinical practice primarily relies on valve-centric parameters and LV remodeling to guide intervention, but does not directly account for myocardial dysfunction.[4] Accordingly, incorporation of AAS may refine risk stratification by identifying patients with impaired myocardial performance beyond valve severity and LV geometry. This concept is aligned with emerging evidence in AS management, where myocardial dysfunction has been proposed as a determinant of earlier intervention.[18,19] Taken together, an integrated framework incorporating valve severity, LV remodeling, and myocardial performance may provide a more comprehensive approach to patient assessment and inform optimal timing of intervention in MAVD.

4.5. Limitations

Several limitations should be acknowledged. First, this was a retrospective, single-center study, which may limit generalizability. Second, AR severity was assessed using an integrative qualitative approach and may be subject to interobserver variability. Third, AAS was derived using SBP and AV mPG as surrogates of afterload and does not fully capture arterial

compliance or valvuloarterial impedance. Fourth, the relatively small number of patients with moderate or greater AR may have limited statistical power in this subgroup. Fifth, additional parameters such as natriuretic peptides and aortic valve calcium burden were not systematically available. Sixth, the timing of AVR as the secondary outcome may have been influenced by physician discretion and institutional practice. Seventh, low-flow, low-gradient AS was not specifically characterized, although patients with LVEF <40% were excluded, limiting inclusion of the most common underlying phenotype. Finally, LVGLS was measured using two vendor platforms, and inter-vendor variability in absolute strain values cannot be fully excluded.

5. CONCLUSIONS

In patients with MAVD, ventricular geometry and afterload-adjusted myocardial performance represent complementary dimensions of LV assessment. IGI reflects structural remodeling under combined pressure–volume loading and is associated with subsequent AVR, whereas AAS provides a load-adjusted measure of myocardial performance and demonstrates independent and incremental prognostic value beyond clinical and structural remodeling indices. An integrated approach incorporating valve severity, LV remodeling, and myocardial performance may improve risk stratification and inform optimal timing of intervention in patients with MAVD.

REFERENCES

1. Egbe AC, Luis SA, Padang R, et al. Outcomes in moderate mixed aortic valve disease: is it time for a paradigm shift? *J Am Coll Cardiol.* 2016;67:2321–2329.

2. Parker MW, Aurigemma GP. The simple arithmetic of mixed aortic valve disease: LVH + volume load = trouble. *J Am Coll Cardiol.* 2016;67:2330–2333.

3. Rashedi N, Popović ZB, Stewart WJ, et al. Outcomes of asymptomatic adults with combined aortic stenosis and regurgitation. *J Am Soc Echocardiogr.* 2014;27:829–837.

4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. *J Am Coll Cardiol.* 2021;77:e25–e197.

5. Khan F, Okuno T, Malebranche D, et al. Transcatheter aortic valve replacement in patients with multivalvular heart disease. *JACC Cardiovasc Interv.* 2020;13:1503–1514.

6. Stassen J, Ewe SH, Hirasawa K, et al. Left ventricular remodelling patterns in patients with moderate aortic stenosis. *Eur Heart J Cardiovasc Imaging.* 2022;23:1326–1335.

7. De Colle C, Paolisso P, Gallinoro E, et al. Association of mild-to-moderate aortic regurgitation with outcomes in heart failure with preserved ejection fraction. *Mayo Clin Proc.* 2023;98:1469–1481.

8. Ajmone Marsan N, Delgado V, Shah DJ, et al. Valvular heart disease: shifting the focus to the myocardium. *Eur Heart J.* 2023;44:28–40.

9. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults. *J Am Soc Echocardiogr.* 2015;28:1–39.e14.

10. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation

of native valvular regurgitation. *J Am Soc Echocardiogr.* 2017;30:303–371.

11.   Thomas JD, Edvardsen T, Abraham T, et al. Clinical applications of strain echocardiography. *J Am Soc Echocardiogr.* 2025;38:985–1020.

12.   Mihos CG, Liu JE, Anderson KM, et al. Speckle-tracking strain echocardiography for LV assessment. *Circulation.* 2025;152:e96–e109.

13.   Maksuti E, Westerhof BE, Ugander M, et al. Cardiac remodeling in valve disease: simulation and validation. *J Appl Physiol (1985).* 2019;126:1377–1389.

14.   Voigt JU, Cvijic M. 2- and 3-dimensional myocardial strain in cardiac health and disease. *JACC Cardiovasc Imaging.* 2019;12:1849–1863.

15.   Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compliance impacts LV afterload and function in AS. *J Am Coll Cardiol.* 2005;46:291–298.

16.   Fortuni F, Butcher SC, van der Kley F, et al. Left ventricular myocardial work in severe aortic stenosis. *J Am Soc Echocardiogr.* 2021;34:257–266.

17.   Généreux P, Schwartz A, Oldemeyer JB, et al. TAVR for asymptomatic severe aortic stenosis. *N Engl J Med.* 2025;392:217–227.

18.   Van Mieghem NM, Elmariah S, Spitzer E, et al. TAVR UNLOAD trial. *J Am Coll Cardiol.* 2025;85:878–890.

Table 1. Baseline Characteristics according to MAVD phenotypes

Variables	Overall population (N=950)	Moderate or greater AS, no AR (N=473)	Moderate or greater AS, Mild AR (N=364)	Moderate or greater AS, Moderate≤ AR (N=113)	p
Age, years	80 (74–85)	81 (75–85)	80 (73–84)	78 (70–84)	0.003
Male	434 (45.7)	213 (45.0)	174 (47.8)	47 (41.6)	0.472
BMI, kg/m2	24.2 (21.8–26.7)	24.2 (22–26.8)	24.3 (21.8–26.7)	23.6 (21.1–26.1)	0.155
SBP, mmHg	132 (120–143)	132 (120–143)	131 (120–143)	133 (116–144)	0.871
DBP, mmHg	71 (64–78)	71.5 (65–80)	70 (63–78)	67 (58–77)	0.001
Hypertension	202 (21.3)	105 (22.2)	80 (22.0)	17 (15.0)	0.227
Diabetes	177 (18.6)	99 (20.9)	66 (18.1)	12 (10.6)	0.039
Myocardial infarction	43 (4.5)	24 (5.1)	14 (3.8)	5 (4.4)	0.697
Congestive heart failure	93 (9.8)	42 (8.9)	37 (10.2)	14 (12.4)	0.505
Stroke	101 (10.6)	58 (12.3)	34 (9.3)	9 (8.0)	0.246
Chronic kidney disease	84 (8.8)	39 (8.2)	49 (10.7)	6 (5.3)	0.170
AS grade					0.058
Moderate	604(63.6)	344 (72.7)	234 (64.3)	74 (65.5)	
Severe	346 (36.4)	129 (27.3)	130 (35.7)	39 (34.5)	
AR grade					0.001
No AR	473 (49.8)	473 (100)	0 (0.0)	0 (0.0)	
Mild	364 (38.3)	0 (0.0)	364 (100)	0 (0.0)	
Moderate	97 (10.2)	0 (0.0)	0 (0.0)	97 (85.8)	
Severe	16 (1.7)	0 (0.0)	0 (0.0)	16 (14.2)	
Echocardiography					

IVS, mm	12 (10–13)	12 (10–13)	12 (11–13)	12 (10–13)	0.930
PW, mm	11 (10–12)	10 (9–12)	11 (10–12)	11 (9–12)	0.166
LVEDD, mm	44 (40–49)	43.4 (39.1–47)	45 (41–48.9)	49 (43–54)	0.001
RWT	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.5 (0.4–0.6)	0.4 (0.4–0.5)	0.001
LVEDV, ml	73 (59–92)	67 (54–85.5)	76 (60.8–92)	92 (74–129)	0.001
LVEDVi, ml/m2	45 (37–56)	41.5 (35–51)	46.8 (38.8–55.9)	59.5 (46.2–75.6)	0.001
LVEF, %	64 (59–68)	64.1 (59.6–68.5)	63.6 (59.2–67.5)	61.9 (56.7–66.3)	0.005
LAVI, ml/m2	48 (38–60)	45.8 (36.8–57.2)	48 (38.3–60.9)	54.6 (42.8–68.6)	0.001
LVMI, g/m2	107 (91–129)	101.6 (87–121)	110.9 (92.5–129.8)	132.1 (102–154.5)	0.001
AV Vmax, m/s	3.5 (3.2–4.2)	3.4 (3.1–4.1)	3.6 (3.2–4.3)	3.8 (3.4–4.6)	0.001
AV mPG, mmHg	27 (22–41)	25.6 (20.7–37.6)	28.1 (22.7–42)	30 (23.4–48)	0.001
AVA, cm2	1.1 (0.9–1.3)	1.2 (0.9–1.3)	1.1 (0.9–1.3)	1.1 (0.8–1.3)	0.161
E/e'	16 (12–21)	15.9 (12.3–21.1)	15.7 (11.9–21.1)	16.7 (12.7–23.4)	0.485
LVGLS, %	16 (14–18)	16.2 (13.7–18.2)	15.7 (13.6–17.5)	15.7 (13.8–17.7)	0.158
TR Vmax, m/s	2.6 (2.3–2.9)	2.6 (2.3–2.8)	2.6 (2.3–2.9)	2.6 (2.4–2.9)	0.553
RVSP, mmHg	32 (26–39)	32 (26.2–38.6)	32 (26.2–38.6)	32 (28–41)	0.381
Afterload-adjusted strain, scaled	0 (-0.6–0.6)	0 (-0.6–0.7)	0 (-0.6–0.5)	0.1 (-0.6–0.8)	0.649
Integrated geometry index, scaled	-0.1 (-0.8–0.7)	-0.3 (-1.0–0.4)	-0.1 (-0.7–0.7)	0.4 (-0.5–1.4)	0.001

Values are presented as median (interquartile range), or as number (percentage), unless otherwise indicated.

Abbreviations: AR = aortic regurgitation; AS = aortic stenosis; AVA = aortic valve area; AV mPG = aortic valve mean pressure gradient; AV Vmax = aortic valve maximal velocity; BMI = body mass index; DBP = diastolic blood pressure; E/e′ = mitral inflow to annular velocity ratio; IVS = interventricular septum; LAVI = left atrial volume index; LVEDD = left ventricular end-diastolic diameter; LVEDV = left ventricular end-diastolic volume; LVEDVi = indexed left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVGLS = left ventricular global longitudinal strain; LVMI = left ventricular mass index; MAVD = mixed aortic valve disease; PW = posterior wall; RVSP = right ventricular systolic pressure; RWT = relative wall thickness; SBP = systolic blood pressure; TR Vmax = tricuspid regurgitation maximum velocity.

Table 2. Risk Factors for the Primary Outcome

Variable	Univariate HR (95% CI)	p	Multivariate HR* (95% CI)	p
Age, per 10-year increase	1.67 (1.31–2.11)	<0.001	—	
Male (vs. Female)	1.16 (0.82–1.66)	0.440	—	
LVEF, per 10% decrease	1.19 (0.92–1.53)	0.176	—	
Combined AR grade				
Moderate AR (vs. mild AR)	1.02 (0.70–1.50)	0.833	1.04 (0.71–1.52)	0.841
Severe AR (vs. mild AR)	1.01 (0.57–1.81)	0.963	1.17 (0.65–2.12)	0.598
AV Vmax, per 1 m/s increase	0.92 (0.73–1.17)	0.529	0.97 (0.76–1.22)	0.773
AV mPG, per 10 mmHg increase	0.95 (0.85–1.07)	0.387	0.97 (0.86–1.08)	0.546
Integrated geometry index (IGI)				
Per unit increase	0.97 (0.83–1.13)	0.676	0.95 (0.81–1.11)	0.502
High IGI (vs. Low IGI)	0.96 (0.67–1.37)	0.813	0.92 (0.64–1.33)	0.656
Afterload-adjusted strain (AAS)				
Per unit decrease	1.58 (1.32–1.88)	<0.001	1.59 (1.30–1.96)	<0.001
Low AAS (vs. High AAS)	1.94 (1.35–2.80)	<0.001	1.76 (1.19–2.59)	0.004

* Adjusted for age, sex, and LVEF. Adjusted hazard ratios are presented for all variables except age, sex, and LVEF, which served as covariates in the multivariable model. Abbreviations: AAS = afterload-adjusted strain; AR = aortic regurgitation; AV mPG = aortic valve mean pressure gradient; AV Vmax = aortic valve maximal velocity; IGI = integrated geometry index; LVEDVi = indexed LV end-diastolic volume; LVEF = LV ejection fraction; LVGLS = LV global longitudinal strain; RWT = relative wall thickness; SBP = systolic blood pressure.

Table 3. Risk Factors for the Secondary Outcome

Variable	Univariate HR (95% CI)	p	Multivariate HR* (95% CI)	p
Age, per 10-year increase	0.91 (0.74–1.10)	0.322	—	
Male (vs. Female)	1.35 (0.95–1.94)	0.097	—	
LVEF, per 10% decrease	1.34 (1.05–1.71)	0.020	—	
Combined AR grade				
Moderate AR (vs. mild AR)	1.74 (1.18–2.56)	0.005	1.71 (1.16–2.51)	0.007
Severe AR (vs. mild AR)	1.46 (0.81–2.63)	0.207	1.34 (0.74–2.42)	0.339
AV Vmax, per 1 m/s increase	2.40 (2.01–2.86)	<0.001	2.44 (2.04–2.92)	<0.001
AV mPG, per 10 mmHg increase	1.43 (1.33–1.53)	<0.001	1.43 (1.33–1.54)	<0.001
Integrated geometry index (IGI)				
Per unit increase	1.22 (1.06–1.41)	0.005	1.18 (1.02–1.36)	0.026
High IGI (vs. Low IGI)	1.45 (1.01–2.08)	0.042	1.36 (0.94–1.95)	0.100
Afterload-adjusted strain (AAS)				
Per unit decrease	1.06 (0.88–1.27)	0.553	0.96 (0.78–1.17)	0.666
Low AAS (vs. High AAS)	0.97 (0.68–1.40)	0.887	0.83 (0.56–1.22)	0.338

* Adjusted for age, sex, and LVEF. Adjusted hazard ratios are presented for all variables except age, sex, and LVEF, which served as covariates in the multivariable model. Abbreviations: AAS = afterload-adjusted strain; AR = aortic regurgitation; AV mPG = aortic valve mean pressure gradient; AV Vmax = aortic valve maximal velocity; IGI = integrated geometry index; LVEDVi = indexed LV end-diastolic volume; LVEF = LV ejection fraction; LVGLS = LV global longitudinal strain; RWT = relative wall thickness; SBP = systolic blood pressure.

Table 4. Subgroup Analysis for the Primary Outcome

Subgroups		N	Adjusted Hazard Ratio* (95% CI) per unit decrease in AAS	p interaction
MAVD phenotypes	Moderate or greater AS, no AR	473	1.68 (1.26-2.23)	
	Moderate or greater AS, Mild AR	364	1.58 (1.12-2.24)	0.919
	Moderate or greater AS, Moderate or greater AR	113	1.35 (0.74-2.47)	
Integrated geometry index	High	430	1.62 (1.18-2.24)	0.686
	Low	520	1.62 (1.23-2.13)	
Myocardial infarction	Yes	43	1.35 (0.70-2.62)	0.834
	No	907	1.56 (1.26-1.94)	
Congestive heart failure	Yes	93	1.52 (0.86-2.68)	0.549
	No	857	1.57 (1.25-1.96)	
AVR at follow-up	Yes	120	1.50 (0.93-2.44)	0.229
	No	830	1.65 (1.31-2.08)	

Abbreviations: AAS = afterload-adjusted strain; AR = aortic regurgitation; AS = aortic stenosis; AVR = aortic valve replacement.

* Adjusted for age, sex, and LVEF

FIGURES

Figure 1. Study flow diagram

Patients were screened from consecutive transthoracic echocardiography studies at Seoul National University Bundang Hospital (January 2015–December 2020). After applying exclusion criteria, 950 patients with moderate or greater AS were categorized according to AR severity.

CIED = cardiac implantable electronic device; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MR = mitral regurgitation; MS = mitral stenosis; SBP = systolic blood pressure.

Figure 2. Integrated echocardiographic framework

The integrated geometry index (IGI) is defined as the z-standardized sum of relative wall thickness (RWT) and indexed LV end-diastolic volume (LVEDVi), reflecting LV geometric remodeling under combined pressure–volume loading. Afterload-adjusted strain (AAS) is calculated as |LVGLS| × (SBP + AV mPG), followed by z-standardization, representing myocardial deformation relative to effective LV afterload. Higher AAS indicates better afterload-adjusted myocardial performance.

AV mPG = aortic valve mean pressure gradient; LVGLS = LV global longitudinal strain; SBP = systolic blood pressure.

Figure 3. Distribution of echocardiographic parameters across MAVD phenotypes

Box-and-whisker plots show LVEDVi, RWT, IGI, LVEF, SBP, AV mPG, LVGLS, and AAS across MAVD phenotypes.

AR = aortic regurgitation; AS = aortic stenosis; AV mPG = aortic valve mean pressure gradient; LVEDVi = indexed LV end-diastolic volume; LVEF = LV ejection fraction; LVGLS = LV global longitudinal strain; RWT = relative wall thickness; SBP = systolic blood pressure.

Figure 4. Kaplan–Meier curves for clinical outcomes

Event-free survival curves for (A) the primary outcome (all-cause death or heart failure hospitalization) and (B) AVR, stratified by MAVD phenotype (left), IGI group (middle), and AAS group (right). P values were derived using the log-rank test.

AR = aortic regurgitation; AS = aortic stenosis; AV = aortic valve; HF = heart failure; IGI = integrated geometry index; AAS = afterload-adjusted strain.

Figure 5. Incremental prognostic value of AAS

(A) Receiver operating characteristic curves for predicting the 1-year primary outcome. Model 1: age, sex, and LVEF (AUC 0.62); Model 2: Model 1 + IGI (AUC 0.63; p=0.881 vs. Model 1); Model 3: Model 1 + AAS (AUC 0.69; p=0.032 vs. Model 1); Model 4: Model 2 + AAS (AUC 0.70; p=0.035 vs. Model 2). (B) Restricted cubic spline showing the association between AAS and predicted 1-year risk (reference: age 70 years, LVEF 50%). Lower AAS values are associated with progressively higher predicted risk in both sexes.

AUC = area under the curve; LVEF = LV ejection fraction

Model	1-year AUC (95% CI)	P$_{difference}$ (vs. Model 1)	P$_{difference}$ (vs. Model 2)
Model 1: age + sex + LVEF	0.62 (0.55-0.69)	.	.
Model 2: Model 1 + IGI	0.63 (0.54-0.70)	0.881	.
Model 3: Model 1 + AAS	0.69 (0.62-0.75)	0.032	0.036
Model 4: Model 1 + IGI + AAS	0.70 (0.63-0.76)	0.031	0.035